Jeanne Bulemfu

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

Paul R. Kalra, John G.F. Cleland, Mark C. Petrie et al. · The Lancet · 2022 · 372 citations · Full text

Medicine, Cardiology, Internal Medicine +11

Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event

Carolyn S.P. Lam, Anna Giczewska, Karen Sliwa et al. · JAMA Cardiology · 2020 · 82 citations · Full text

Medicine, Cardiology, Pharmacotherapy +13

Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial

John G.F. Cleland, Philip A. Kalra, Pierpaolo Pellicori et al. · European Heart Journal · 2024 · 39 citations · Full text

Medicine, Hematology, Internal Medicine +17

Added value of frailty and social support in predicting risk of 30-day unplanned re-admission or death for patients with heart failure: An analysis from OPERA-HF

Ioanna Sokoreli, John G.F. Cleland, Steffen Pauws et al. · International Journal of Cardiology · 2018 · 34 citations

Medicine, Cardiology, Geriatric Medicine +17

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

Faı̈ez Zannad, Christopher M. O’Connor, Javed Butler et al. · The Lancet · 2025 · 32 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +17